{"transactions":[{"id":918935,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Performance Stock Options (Right to Buy)","published_at":"2026-02-05T02:30:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":106250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date."}],"balance_after":106250,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":106250},"source":{"system":"sec-edgar","filing":"0001831216-26-000005","document":"form4-02042026_090205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000005/form4-02042026_090205.xml","form_type":"4"}},{"id":918934,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T02:30:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":250000,"derivative":{"exercise_price":25.65,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001831216-26-000005","document":"form4-02042026_090205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000005/form4-02042026_090205.xml","form_type":"4"}},{"id":939044,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":4.87,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939043,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":4.87,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939042,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"sale","planned":false,"acquired":false,"shares":35003,"price":28.99,"value":1014736.97,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":542761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939041,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"sale","planned":false,"acquired":false,"shares":14997,"price":28.6,"value":428914.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":577764,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939040,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-14","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":4.87,"value":243500.0,"ownership":{"direct":true},"balance_after":592761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939039,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"sale","planned":false,"acquired":false,"shares":200,"price":28.49,"value":5698.0,"ownership":{"direct":true},"balance_after":542761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939038,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"sale","planned":false,"acquired":false,"shares":49800,"price":27.6,"value":1374480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":542961,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939037,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-13","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":4.87,"value":243500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4."}],"balance_after":592761,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":939036,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2026-01-15T02:30:06.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":28.34,"value":283400.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Myles Properties Inc., of which the Reporting Person is President."}],"balance_after":144846,"source":{"system":"sec-edgar","filing":"0001831216-26-000003","document":"form4-01142026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121626000003/form4-01142026_090101.xml","form_type":"4"}},{"id":959290,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"gift","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":542881,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":959289,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":6046,"price":31.39,"value":189783.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $31.39, and the range of prices was between $31.00 and $31.595. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":551881,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":959288,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":43729,"price":30.4,"value":1329361.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $30.40, and the range of prices was between $30.00 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided"}],"balance_after":557927,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":959287,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2025-12-24T02:41:49.000Z","date":"2025-12-19","kind":"sale","planned":false,"acquired":false,"shares":1225,"price":28.08,"value":34398.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.08, and the range of prices was between $28.075 and $28.130. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 11, 2024, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be understated by 60 shares. That error has been corrected in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,488 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":601656,"source":{"system":"sec-edgar","filing":"0001831216-25-000004","document":"form4-12242025_021245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183121625000004/form4-12242025_021245.xml","form_type":"4"}},{"id":1235077,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T21:20:52.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":205000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001415889-25-006160","document":"form4-03032025_090348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925006160/form4-03032025_090348.xml","form_type":"4"}},{"id":1335020,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2024-12-12T00:56:03.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":300,"price":9.39,"value":2817.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":598333,"source":{"system":"sec-edgar","filing":"0001415889-24-029027","document":"form4-12122024_121200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029027/form4-12122024_121200.xml","form_type":"4"}},{"id":1335019,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2024-12-12T00:56:03.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":13314,"price":8.66,"value":115299.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":598633,"source":{"system":"sec-edgar","filing":"0001415889-24-029027","document":"form4-12122024_121200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029027/form4-12122024_121200.xml","form_type":"4"}},{"id":1335018,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2024-12-12T00:56:03.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":12452,"price":9.38,"value":116799.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $9.38, and the range of prices was between $8.89 and $9.67. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":611947,"source":{"system":"sec-edgar","filing":"0001415889-24-029027","document":"form4-12122024_121200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029027/form4-12122024_121200.xml","form_type":"4"}},{"id":1335017,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2024-12-12T00:56:03.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2022, the Reporting Person was granted certain performance restricted stock units (\"PRSUs\") for 75,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,490 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024."}],"balance_after":624399,"source":{"system":"sec-edgar","filing":"0001415889-24-029027","document":"form4-12122024_121200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029027/form4-12122024_121200.xml","form_type":"4"}},{"id":1658079,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T22:30:38.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":195000,"derivative":{"exercise_price":15.25,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001415889-24-002610","document":"form4-02052024_050218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924002610/form4-02052024_050218.xml","form_type":"4"}},{"id":1730704,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-23T00:00:20.000Z","date":"2023-11-22","kind":"sale","planned":false,"acquired":false,"shares":6653,"price":13.89,"value":92410.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the\nvesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a\ndiscretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":574099,"source":{"system":"sec-edgar","filing":"0001415889-23-015458","document":"form4-11222023_071109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015458/form4-11222023_071109.xml","form_type":"4"}},{"id":1730703,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-23T00:00:20.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":200,"price":15.32,"value":3064.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the\nvesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a\ndiscretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":580752,"source":{"system":"sec-edgar","filing":"0001415889-23-015458","document":"form4-11222023_071109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015458/form4-11222023_071109.xml","form_type":"4"}},{"id":1730702,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-23T00:00:20.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":6776,"price":14.87,"value":100759.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the\nvesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a\ndiscretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":580952,"source":{"system":"sec-edgar","filing":"0001415889-23-015458","document":"form4-11222023_071109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015458/form4-11222023_071109.xml","form_type":"4"}},{"id":1730701,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-23T00:00:20.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2022, the Reporting Person was granted certain performance restricted stock units (\"PRSUs\") for 75,000 shares, which are subject to vesting\nupon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on\nNovember 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023."}],"balance_after":587728,"source":{"system":"sec-edgar","filing":"0001415889-23-015458","document":"form4-11222023_071109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015458/form4-11222023_071109.xml","form_type":"4"}},{"id":1743351,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-13T22:30:15.000Z","date":"2023-11-08","kind":"sale","planned":true,"acquired":false,"shares":200,"price":17.61,"value":3522.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $17.61, and the range of prices were between $17.52 and $17.69. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":561270,"source":{"system":"sec-edgar","filing":"0001415889-23-015041","document":"form4-11132023_051101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015041/form4-11132023_051101.xml","form_type":"4"}},{"id":1749302,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-04T01:39:06.000Z","date":"2023-11-03","kind":"sale","planned":true,"acquired":false,"shares":541,"price":17.51,"value":9472.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $17.51, and the range of prices were between $17.50 and $17.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":561470,"source":{"system":"sec-edgar","filing":"0001415889-23-014792","document":"form4-11042023_011159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923014792/form4-11042023_011159.xml","form_type":"4"}},{"id":1749301,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-04T01:39:06.000Z","date":"2023-11-02","kind":"sale","planned":true,"acquired":false,"shares":3332,"price":15.36,"value":51179.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $15.36, and the range of prices were between $15.01 and $15.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":562011,"source":{"system":"sec-edgar","filing":"0001415889-23-014792","document":"form4-11042023_011159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923014792/form4-11042023_011159.xml","form_type":"4"}},{"id":1749300,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-11-04T01:39:06.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":6668,"price":15.02,"value":100153.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $15.02, and the range of prices were between $15.00 and $15.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":565343,"source":{"system":"sec-edgar","filing":"0001415889-23-014792","document":"form4-11042023_011159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923014792/form4-11042023_011159.xml","form_type":"4"}},{"id":1775229,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CH. DISCOV. & NON-CLIN DEV OFF"}}],"security":"Common Stock","published_at":"2023-09-21T21:00:09.000Z","date":"2023-09-19","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":12.67,"value":253400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.67, and the range of prices were between $12.31 and $12.85. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,446 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2022, and 7,664 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023."}],"balance_after":572011,"source":{"system":"sec-edgar","filing":"0001415889-23-013474","document":"form4-09212023_050902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923013474/form4-09212023_050902.xml","form_type":"4"}},{"id":2035002,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-02T22:32:06.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.87,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-23-006289","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919123006289/doc4.xml","form_type":"4"}},{"id":2412775,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T00:15:48.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":118750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":118750,"derivative":{"exercise_price":7.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":118750},"source":{"system":"sec-edgar","filing":"0001415889-22-001061","document":"form4-02032022_040238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588922001061/form4-02032022_040238.xml","form_type":"4"}},{"id":2472820,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2021-12-14T21:03:49.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":10000,"price":10.3,"value":103000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"T he weighted average sale price for the transaction reported was $10.30, and the range of prices was between $10.23 and $10.50. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 589 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021, and 491 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021."}],"balance_after":582901,"source":{"system":"sec-edgar","filing":"0001415889-21-005860","document":"form4-12142021_011237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921005860/form4-12142021_011237.xml","form_type":"4"}},{"id":2969373,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-11-23T21:34:14.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":154846,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Myles Properties Inc., of which the Reporting Person is President."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":154846},"source":{"system":"sec-edgar","filing":"0001209191-20-059976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059976/doc4.xml","form_type":"4"}},{"id":2969372,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-11-23T21:34:14.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":12831,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12831},"source":{"system":"sec-edgar","filing":"0001209191-20-059976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059976/doc4.xml","form_type":"4"}},{"id":2969371,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-11-23T21:34:14.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":154846,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Myles Properties Inc., of which the Reporting Person is President."}],"balance_after":154846,"source":{"system":"sec-edgar","filing":"0001209191-20-059976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059976/doc4.xml","form_type":"4"}},{"id":2969370,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-11-23T21:34:14.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":12831,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee."}],"balance_after":12831,"source":{"system":"sec-edgar","filing":"0001209191-20-059976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059976/doc4.xml","form_type":"4"}},{"id":2972610,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:59:06.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":179340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":179340,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":179340},"source":{"system":"sec-edgar","filing":"0001209191-20-059524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059524/doc4.xml","form_type":"4"}},{"id":2972609,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":67696,"kind":"person","name":"Myles David C.","position":1,"cik":"0001831216","reported_name":"Myles David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-11-19T23:59:06.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":143472,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":591821,"source":{"system":"sec-edgar","filing":"0001209191-20-059524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059524/doc4.xml","form_type":"4"}}]}